Starton Therapeutics

×

Transforming therapies with proprietary dermal delivery technology, so people with cancer live better, longer

Start a new standard

Starton Therapeutics is transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, longer.

Targeted continuous delivery

We transform FDA-approved medicines and leverage our dermal delivery systems to establish new profiles. Our platform technology enables lower but longer drug exposure and the potential for improved efficacy.

Careers

Building a team dedicated to delivering breakthrough, transformative products for patients with blood cancers.We offer comprehensive and competitive health, financial, paid time off and many other benefits designed to promote the health and well-being of our employees and their families.

News and Events

June 21, 2024

Starton Therapeutics Announces 100% Partial Response or Better in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Phase 1b Clinical Trial

PARAMUS, N.J., – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today positive interim top-line data from its…

May 20, 2024

U.S. Patent and Trademark Office Grants US Patent # 11,975,112 for “Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine”

PARAMUS, N.J., – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today that the U.S. Patent and Trademark…